Draupnir Bio intends to develop a new type of cholesterol-lowering medicine that prevents blood clots in the heart more effectively than the current medicine. The company is developing a platform for exploring the glycome to develop novel therapeutics, based on array technology, protein chemistry, and advanced carbohydrate chemistry. The company isable to synthesize, screen, and select highly potent and specific heparan sulfate glycomimetic drug candidates in cardiovascular, inflammatory, and infectious diseases.

Biotechnology

Health Care

Pharmaceutical

Therapeutics

Draupnir Bio

Andrew Hotchkiss

Simon Glerup

Simon Feldbæk Nielsen

Joachim Pold Vilstrup

Casper Tind Hansen

Camilla Gustafsen

Draupnir Bio

Org chart

Similar companies